Ebvallo for Transplant-Related Cancer

Why is the FDA reviewing Ebvallo again?

Pierre Fabre says the accepted application includes additional participants and longer follow-up from the ALLELE trial, alongside evidence from expanded access programs and European use. The proposed indication covers adults and children aged two or older with Epstein-Barr virus-positive post-transplant lymphoproliferative disease, or EBV-positive PTLD, after previous therapy. The company reports a target FDA action date of March 31, 2027; that date does not guarantee approval. [Manufacturer announcement](https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-for-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-302908451.html)

The renewed application follows an FDA refusal in January. According to Pierre Fabre's account of subsequent regulatory discussions, a study with one treatment group could support an application when evaluated against an appropriate historical comparison group. Such comparisons use outcomes from previously treated patients. Their interpretation depends on whether those patients sufficiently resemble trial participants in disease severity, previous treatment and other factors affecting survival. [Pierre Fabre regulatory update](https://www.pierrefabrepharmaceuticals.com/node/9)

How does tabelecleucel target cancer after a transplant?

Transplant recipients often need medicines that suppress immune activity. This can weaken control of Epstein-Barr virus, allowing infected B cells to multiply and sometimes develop into cancer. Tabelecleucel contains donor T cells selected and expanded in a laboratory to recognize those infected cells. It aims to restore a targeted immune response against the malignancy. [EMA medicine overview](https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo)

The published ALLELE phase 3 analysis included 43 treated patients whose disease had returned or resisted previous treatment. Seven of 14 stem-cell transplant recipients and 15 of 29 solid-organ transplant recipients achieved an objective response, meaning their cancer decreased or became undetectable under the study's assessment criteria. Together, that represents approximately half the participants. These are results from the analysis published in The Lancet Oncology in 2024, rather than newly released response figures from the current application. [Published ALLELE study](https://pubmed.ncbi.nlm.nih.gov/38309282/)

What uncertainties and treatment risks still matter?

ALLELE had no randomized comparison group, so its response results cannot establish how much tabelecleucel improves survival compared with another treatment. Tumor response also does not necessarily mean cure. The study was funded by Atara Biotherapeutics, a relevant disclosure when interpreting its findings. Serious adverse events occurred in this medically vulnerable population, although events occurring during treatment are not automatically caused by the therapy. [Published trial and funding disclosure](https://pubmed.ncbi.nlm.nih.gov/38309282/)

European regulators authorized Ebvallo under exceptional circumstances because the disease's rarity prevented collection of complete evidence. Continued evaluation remains necessary. The EMA identifies serious risks including inflammatory tumor flare and graft-versus-host disease, in which donor immune cells attack the recipient's tissues. Treatment therefore requires specialist supervision and facilities able to manage urgent complications. [EMA benefit-risk assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo)